ArticleLe infezioni in medicina2026
Enterovirus respiratory infection in adults: an overlooked clinical burden emerging in the post-pandemic era.
Article in Le infezioni in medicina, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enterovirus (EV) is increasingly identified as a cause of acute respiratory infections in adults, yet its clinical burden in real-world settings remains poorly characterized. Individuals with underlying chronic respiratory conditions, such as asthma or chronic obstructive pulmonary disease, are at heightened risk of severe respiratory compromise from EV infection, as they are from many other respiratory pathogens. Following an increase in EV circulation in our healthcare district in recent years, as reported in other countries, we performed a retrospective analysis of all adults (≥18 years) including only acute respiratory EV infection documented by multiplex RT-PCR of nasopharyngeal swabs between January and December 2024. Seventy patients were included (mean age 68.5 ± 19.2 years, balanced sex distribution) with a high prevalence of comorbidities, particularly cardiovascular disease (37%) and chronic respiratory disease (34%). The clinical presentation was dominated by cough (74%) and dyspnea (70%), whereas fever was less common. At presentation, 41% (n=29) met criteria for acute respiratory failure, defined as a partial pressure of oxygen <60 mmHg on arterial blood gas. Chest radiography was abnormal in most cases (74%), showing predominantly interstitial markings (51%), followed by consolidations (16%) and mixed patterns (7%). Inflammatory markers were frequently elevated, with C-reactive Protein >0.5 mg/dL in 93.7% and leukocytosis in 44.3%. Forty patients (57%) required hospital admission, 35 (50%) needed oxygen or ventilatory support (predominantly low-flow oxygen), and seven patients (10%) required escalation to advanced support (high-flow oxygen in four cases, non-invasive ventilation in two, and invasive mechanical ventilation in one). Two patients (2.8%) were admitted to the Intensive Care Unit, and 30-day mortality was 2.8% (n=2). In our cohort, patients with COPD (n = 14) had the most severe course (respiratory failure 57%, oxygen requirement 64%, hospitalization 71%, 1 IMV, 1 death), whereas those with asthma (n = 7) had a comparatively milder clinical course (respiratory failure 43%, no ventilatory support, no deaths). Overall, in our real-world scenario, EV infection was associated with frequent gas-exchange impairment, radiographic abnormalities, and clinically meaningful resource utilization in adults, particularly among those with chronic respiratory disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.